Related Experiment Video

Updated: Jun 22, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

Tovorafenib: First Approval

Sohita Dhillon1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|July 5, 2024
PubMed

Insights

Tovorafenib (OJEMDA™) is a new oral medication approved for pediatric low-grade gliomas with BRAF alterations. This targeted therapy offers a new treatment option for relapsed or refractory cases.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Paediatric low-grade gliomas (pLGG) often involve MAPK pathway alterations, including BRAF mutations or fusions.
  • These alterations lead to abnormal intracellular signaling, driving tumor growth.
  • Targeted therapies addressing these specific genetic drivers are crucial for effective treatment.

Purpose of the Study:

  • To summarize the development milestones of tovorafenib.
  • To highlight its first FDA approval for specific pediatric brain tumors.
  • To provide an overview of its mechanism of action and clinical development.

Main Methods:

  • Tovorafenib is a selective, brain-penetrant, type II RAF kinase inhibitor.
  • It targets mutant BRAF V600E, wild-type BRAF, wild-type CRAF kinases, and BRAF fusions.
  • Development involved the pivotal phase 2 FIREFLY-1 study.

Main Results:

  • Tovorafenib (OJEMDA™) received its first US approval in April 2024.
  • Approval is for patients aged ≥6 months with relapsed or refractory pLGGs harboring a BRAF fusion, rearrangement, or V600 mutation.
  • Accelerated approval was based on response rate and duration of response in the FIREFLY-1 study.

Conclusions:

  • Tovorafenib represents a significant advancement in treating pediatric low-grade gliomas with specific BRAF alterations.
  • Its targeted mechanism addresses the underlying molecular drivers of these tumors.
  • Ongoing clinical development worldwide signifies its potential broader impact.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.5K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
446
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K